Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intercept Pharmaceuticals, Inc. - Common Stock (NQ:ICPT)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Intercept Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why Freyr Battery (FREY) Stock Could Be the Best EV Bet
Freyr Battery (FREY) stock is a hot topic among traders on Wednesday after Morgan Stanley weighed in on the electric vehicle (EV) company. 
Via InvestorPlace
Intercept Pharma Summarizes Key Actions in Strategic Financial Repositioning
Via Benzinga
Why Is Intercept Pharmaceuticals (ICPT) Stock Up Today?
Intercept Pharmaceuticals (ICPT) stock is on the move Wednesday after giving investors an update on how it improved its financials. 
Via InvestorPlace
Intercept Pharmaceutical Stock Shows Market Leadership; Earns 92 RS Rating
On Tuesday, Intercept Pharmaceutical stock had its Relative Strength Rating upgraded to 92, up from 89 a day earlier. 
Via Investor's Business Daily
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Monday, 8/29, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
Intercept Settles Ocaliva Litigation With Reddy's Lab
Via Benzinga
Where Intercept Pharmaceuticals Stands With Analysts
Within the last quarter, Intercept Pharmaceuticals (NASDAQ:ICPT) has observed the following analyst ratings: 
Via Benzinga
Intercept Shares Jump After Reissuing Annual Guidance
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) completed the sale of its international business for $405 million in upfront consideration. 
Via Benzinga
What 6 Analyst Ratings Have To Say About Intercept Pharmaceuticals
Intercept Pharmaceuticals (NASDAQ:ICPT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Raymond James Maintains Outperform Rating for Intercept Pharmaceuticals: Here's What You Need To Know
Raymond James has decided to maintain its Outperform rating of Intercept Pharmaceuticals (NASDAQ:ICPT) and raise its price target from $26.00 to $28.00. Shares of Intercept Pharmaceuticals are trading... 
Via Benzinga
Stocks That Made New Highs On Friday, Aug. 19
On Friday, in spite of the stock market being down, there were several stocks that actually made new highs. 
Via Talk Markets
General Motors, Foot Locker And Some Other Big Stocks Recording Gains On Friday
  GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 145% to $38.45 on continued volatility following the company's IPO on Thursday. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Needham Cuts Price Target On This NASH-Focused Stock As Its Awaits Visibility On Regulatory Path
Via Benzinga
Regulatory Update On Intercept Pharma's Obeticholic Acid For NASH Delayed Again
Via Benzinga
Analysts Expect Clarity Imminent On Intercept's NASH Story
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Intercept Pharmaceuticals: Q2 Earnings Insights
  Intercept Pharmaceuticals (NASDAQ:ICPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyst Ratings for Intercept Pharmaceuticals
Intercept Pharmaceuticals (NASDAQ:ICPT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Thursday, 7/28, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
7 Biotech Stocks to Buy for Q3
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
Analyst Ratings for Intercept Pharmaceuticals
Over the past 3 months, 4 analysts have published their opinion on Intercept Pharmaceuticals (NASDAQ:ICPT) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Why Did Intercept Pharmaceuticals (ICPT) Stock Fall 10% Today?
A fresh press release from Intercept Pharmaceuticals reveals positive data from an important clinical trial. Yet, ICPT stock is dropping. 
Via InvestorPlace
Intercept Shares Fall After Interim Analysis On Late-Stage NASH Study
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) announced positive topline results from a new interim analysis of its ongoing pivotal Phase 3 REGENERATE trial of OCA in patients with liver fibrosis due... 
Via Benzinga
This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session
Gainers United Maritime Corporation (NASDAQ: USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp. 
Via Benzinga
Jim Cramer Prefers This Oil Stock Over Occidental Petroleum
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) is a total spec. 
Via Benzinga
Intercept Pharmaceuticals's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, Intercept Pharmaceuticals's (NASDAQ:ICPT) reported sales totaled $88.58 million. Despite a 52.36% increase in earnings, the company posted a loss of... 
Via Benzinga
First Patient Dosed in Phase 2 Study of Intercept's OCA and Bezafibrate Combination for Primary Biliary Cholangitis
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) dosed first patient in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for the treatment of patients... 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.